Chen X X, Zhou C C
Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China.
Zhonghua Zhong Liu Za Zhi. 2017 Jun 23;39(6):401-404. doi: 10.3760/cma.j.issn.0253-3766.2017.06.001.
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. However, most of patients will develop resistance to TKIs treatment due to the emergence of the T790M mutation. The third-generation EGFR-TKI is highly selective and efficient for activating mutants (EGFR sensitive mutations) and resistance mutant (T790M+ ). This review summarizes the mechanism and clinical efficacy of the third-generation EGFR-TKI in NSCLC patients.
表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）是表皮生长因子受体（EGFR）激活突变的非小细胞肺癌（NSCLC）患者的标准治疗方法。然而，由于T790M突变的出现，大多数患者会对TKIs治疗产生耐药性。第三代EGFR-TKI对激活突变体（EGFR敏感突变）和耐药突变体（T790M+）具有高度选择性和高效性。本文综述了第三代EGFR-TKI在NSCLC患者中的作用机制和临床疗效。
